BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28320467)

  • 1. The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review.
    Siyam T; Ross S; Campbell S; Eurich DT; Yuksel N
    BMC Womens Health; 2017 Mar; 17(1):22. PubMed ID: 28320467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
    JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
    Powell CB; Alabaster A; Le A; Stoller N; Armstrong MA; Raine-Bennett T
    Psychooncology; 2020 Feb; 29(2):331-338. PubMed ID: 31654466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
    Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.
    Michelsen TM; Dørum A; Tropé CG; Fosså SD; Dahl AA
    Int J Gynecol Cancer; 2009 Aug; 19(6):1029-36. PubMed ID: 19820364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.
    Meiser B; Price MA; Butow PN; Karatas J; Wilson J; Heiniger L; Baylock B; Charles M; McLachlan SA; Phillips KA
    Fam Cancer; 2013 Mar; 12(1):101-9. PubMed ID: 23203849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
    Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
    Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
    Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexuality and quality of life in women with a prior diagnosis of breast cancer after risk-reducing salpingo-oophorectomy.
    Tucker PE; Saunders C; Bulsara MK; Tan JJ; Salfinger SG; Green H; Cohen PA
    Breast; 2016 Dec; 30():26-31. PubMed ID: 27592287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
    Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
    Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
    Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Garcia C; Lyon L; Conell C; Littell RD; Powell CB
    Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy.
    DeLeo MJ; Domchek SM; Kontos D; Conant E; Chen J; Weinstein S
    AJR Am J Roentgenol; 2015 Mar; 204(3):669-73. PubMed ID: 25714301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
    Johansen N; Liavaag AH; Tanbo TG; Dahl AA; Pripp AH; Michelsen TM
    Gynecol Oncol; 2016 Jan; 140(1):101-6. PubMed ID: 26597462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant.
    Zilski N; Speiser D; Bartley J; Roehle R; Blohmer JU; Keilholz U; Goerling U
    J Sex Med; 2023 Dec; 21(1):33-39. PubMed ID: 37973412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
    Wang Y; Song Z; Zhang S; Wang X; Li P
    Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical decision making in premenopausal
    Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
    J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.